| Literature DB >> 32476544 |
Sheldon E Litwin1,2, Ted D Adams3,4, Lance E Davidson3,5, Rodrick McKinlay6, Steven C Simper6, Lauren Ranson7, Steven C Hunt3,8.
Abstract
Background Progressive cardiac remodeling and worsening myocardial function over time have been proposed as potential mediators of heart failure in obesity. Methods and Results We serially assessed cardiac structure and function in 254 subjects participating in a longitudinal study of obesity. Demographic, clinical, laboratory, and echocardiographic features were determined at baseline and 2-, 6-, and 11-year follow-up. We measured body mass index (BMI) exposure as the area under the curve of the BMI at each of the 4 visits. At enrollment, mean age of the subjects was 47 years, 79% were women, mean BMI was 44 kg/m2, 26% had diabetes mellitus, 48% had hypertension, and 53% had hyperlipidemia. Between baseline and 11 years, BMI increased by 1.1 and 0.3 kg/m2 in men and women, respectively. There were modest increases in left ventricular (LV) end-diastolic volume, LV mass, and left atrial volume, and significant decreases in early/late mitral diastolic flow velocity ratio and E wave deceleration time. However, there were no significant changes in LV ejection fraction or ratio of early mitral diastolic flow velocity/early mitral annular velocity, whereas right ventricular fractional area change increased. Significant predictors of the change in LV mass were male sex, baseline BMI, BMI area under the curve, and change in LV stroke volume, but not smoking, hypertension, or diabetes mellitus. Conclusions In long-standing, persistent severe obesity, there was evidence of cardiac remodeling over a period of 11 years, but no clear worsening of systolic or diastolic function. Measures of remodeling were most strongly related to BMI. The observed changes might predispose to heart failure with preserved ejection fraction, but are not classic for an evolving dilated cardiomyopathy.Entities:
Keywords: heart failure; hypertension; hypertrophy; obesity
Mesh:
Year: 2020 PMID: 32476544 PMCID: PMC7429060 DOI: 10.1161/JAHA.119.014542
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Age‐Adjusted Clinical Parameters at Baseline and 11‐Year Follow‐Up
| Variable | Men (n=53) | Women (n=201) | Both | ||
|---|---|---|---|---|---|
| Baseline | 11 y | Baseline | 11 y |
| |
| Age, y | 49.1±1.5 | 60.2±1.5 | 46.7±0.8 | 57.7±0.8 | <0.001 |
| Weight, kg | 149.0±2.9 | 149.5±3.7 | 117.8±1.5 | 115.0±1.9 | NS |
| BMI, kg/m2 | 45.6±0.9 | 46.7±1.2 | 43.5±0.5 | 43.8±0.6 | NS |
| BMI AUC | N/A | 46.3±1.0 | N/A | 43.3±0.5 | N/A |
| Waist, cm | 137.4±2.3 | 142.3±2.7 | 129.1±1.2 | 132.5±1.4 | <0.001 |
| % Body fat | 44.1±0.6 | 45.5±0.8 | 53.2±0.3 | 54.0±0.4 | <0.05 |
| Fat free mass, kg | 81.3±1.1 | 77.5±1.5 | 54.9±0.6 | 52.4±0.7 | <0.001 |
| LDL, mg/dL | 103.8±3.8 | 103.5±4.4 | 107.8±1.9 | 118.8±2.2 | <0.001 |
| HDL, mg/dL | 37.1±1.3 | 36.4±1.5 | 48.2±0.7 | 49.6±0.8 | NS |
| Triglycerides, mg/dL | 175.8±14.7 | 154.3±10.2 | 176.8±7.6 | 145.7±5.2 | <0.001 |
| Glycosylated hemoglobin, % | 5.98±0.13 | 6.53±0.22 | 5.84±0.07 | 6.32±0.11 | <0.001 |
| HOMA‐IR | 5.05±0.61 | 6.88±1.5 | 3.89±0.31 | 5.88±0.78 | NS |
| Systolic BP, mm Hg | 132.6±2.3 | 122.6±2.4 | 124.4±1.2 | 125.0±1.2 | NS |
| Diastolic BP, mm Hg | 76.5±1.5 | 69.5±1.3 | 70.6±0.7 | 69.7±0.7 | NS |
| Heart rate, bpm | 73.4±1.8 | 70.5±1.5 | 73.8±0.9 | 70.2±0.8 | <0.01 |
| Treadmill time, s | 690±26 | 642±38 | 540±13 | 537±16 | NS |
| Hypertension, % | 55 | 72 | 47 | 59 | <0.05 |
| Diabetes mellitus, % | 38 | 53 | 23 | 41 | <0.001 |
| Dyslipidemia, % | 77 | 91 | 46 | 59 | NS |
Data are shown as mean±SEM or percentage. AUC indicates area under the curve; BMI, body mass index; BP, blood pressure; bpm, beats per minute; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic Model Assessment of Insulin Resistance; LDL, low‐density lipoprotein; N/A, not applicable; and NS, not significant.
P value from testing for sex‐ and age‐adjusted 11‐year changes for men and women combined, except for age, which was unadjusted. P values were adjusted for 19 multiple comparisons by the Bonferroni test.
Sample size for treadmill time was 49 men and 185 women at baseline and 15 men and 78 women at follow‐up.
Blood Pressure Medication Use at Baseline and 11‐Year Follow‐Up
| Class of Drugs | Baseline (n=254) | 11 y (n=254) |
|---|---|---|
| β Adrenergic blocking agents | 3 | 13* |
| Calcium channel blocking agents | 13 | 13 |
| Angiotensin‐converting enzyme inhibitors | 14 | 21* |
| Angiotensin receptor blocking agents | 10 | 24* |
Data are shown as percentage of patients taking these agents. Patients may have taken >1 class of medications. *P<0.05 vs baseline.
Age‐Adjusted Echocardiographic Parameters at Baseline and 11‐Year Follow‐Up
| Variables | Men (n=53) | Women (n=201) |
| ||
|---|---|---|---|---|---|
| Baseline | 11 y | Baseline | 11 y | Change | |
| LV end diastolic volume, mL | 107±3.8 | 131±3.9† | 94±1.9 | 107±2.0† | <0.001 |
| LV mass, g | 229±6.7 | 273±7.3† | 177±3.4 | 191±3.7† | <0.001 |
| LV mass/LV end diastolic volume, g/mL | 2.27±0.09 | 2.17±0.06 | 2.00±0.04 | 1.84±0.03 | 0.010 |
| LV mass/height2.7, g/m2.7 | 46.1±1.6 | 57.5±1.9† | 46.2±0.8 | 52.2±1.0† | <0.001 |
| Relative wall thickness | 0.54±0.017 | 0.50±0.013 | 0.51±0.009 | 0.47±0.007† | <0.001 |
| LV ejection fraction, % | 60.6±1.4 | 62.8±1.3 | 61.4±0.7 | 62.4±0.7 | NS |
| LA diameter, cm | 4.1±0.7 | 4.3±0.6 | 3.8±0.4 | 3.9±0.3 | 0.004 |
| LA volume, mL | 65±3.0 | 85±3.1† | 47±1.5 | 54±1.6† | <0.001 |
| RV fractional area change, % | 38±1.4 | 44±1.3† | 42±0.7 | 45±0.7† | <0.001 |
| E/A | 1.27±0.04 | 1.03±0.04† | 1.20±0.2 | 0.91±0.2† | <0.001 |
| E deceleration time, ms | 203±6.3 | 179±6.2† | 203±3.2 | 190±3.2† | <0.001 |
| E/e’ | 9.02±0.85 | 9.45±0.51 | 9.25±0.44 | 9.40±0.26† | NS |
E indicates early diastolic mitral inflow velocity; E/A, ratio of early/late mitral diastolic flow velocities; E/e’, ratio of early mitral diastolic flow velocity/early mitral annular velocity; LA, left atrial; LV, left ventricular; and RV, right ventricular.
* P‐value from testing for gender‐ and age‐adjusted 11‐year changes for males and females combined.
† P<0.01 for gender‐specific 11‐year changes. All P‐values were adjusted for 10 multiple comparisons by the Bonferroni test.
Figure 1Changes in patterns of left ventricular (LV) geometry over time.
LV geometry was classified into 1 of 4 categories based on LV mass index (LV mass/height2.7) and relative wall thickness. At baseline, concentric remodeling was the most common pattern in both sexes. After 11 years of follow‐up, there was a shift toward less concentric remodeling and more concentric hypertrophy in both men and women.
Figure 2Changes in patterns of left ventricular (LV) geometry between baseline and 11 years in overall cohort (A) and the subgroup of patients without a diagnosis of hypertension at either visit (B).
Absolute numbers of patients in each category are shown. LVH indicates LV hypertrophy.
Predictors of Changes in Cardiac Structure and Function Over Time
| Baseline Variable Predictors of Change | Δ LV Mass | Δ LVdV | Δ RWT | Δ LA Diameter | Δ LA Volume | Δ E/A | Δ E Decel Time | Δ RV Fractional Shortening |
|---|---|---|---|---|---|---|---|---|
| Sex | <0.001 | 0.06 | 0.69 | 0.70 | 0.01 | 0.37 | 0.35 | 0.14 |
| Age | 0.77 | 0.54 | 0.79 | 0.79 | 0.37 | 0.41 | 0.10 | 0.90 |
| BMI | 0.001 | 0.04 | 0.54 | 0.34 | 0.93 | 0.53 | 0.55 | 0.23 |
| Smoking status | 0.14 | 0.17 | 0.23 | 0.95 | 0.94 | 0.96 | 0.75 | 0.87 |
AUC indicates area under the curve; BMI, body mass index; BP, blood pressure; E Decel time, E wave deceleration time; E/A, ratio of early/late mitral diastolic flow velocities; HbA1c, glycosylated hemoglobin; LA, left atrial; LV, left ventricular; LVdV, LV diastolic volume; RV, right ventricular; and RWT, relative wall thickness.
Changes are defined as examination 4 minus examination 1. P values are unadjusted for multiple comparisons, but should be <0.006 to adjust for 8 dependent variables using the Bonferroni adjustment.
P<0.05.